ValuEngine upgraded shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) from a strong sell rating to a sell rating in a research note issued to investors on Friday.

ITCI has been the subject of several other research reports. Piper Jaffray Companies downgraded Intra-Cellular Therapies from an overweight rating to a neutral rating and cut their price objective for the company from $22.00 to $10.00 in a report on Monday, May 1st. Zacks Investment Research downgraded Intra-Cellular Therapies from a hold rating to a sell rating in a report on Tuesday, May 9th. Cantor Fitzgerald cut their price objective on Intra-Cellular Therapies from $32.00 to $29.00 and set an overweight rating for the company in a report on Tuesday, May 2nd. Ladenburg Thalmann Financial Services downgraded Intra-Cellular Therapies from a buy rating to a neutral rating in a report on Tuesday, May 2nd. Finally, Leerink Swann downgraded Intra-Cellular Therapies from an outperform rating to a market perform rating and cut their price objective for the company from $29.00 to $10.00 in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $24.43.

Intra-Cellular Therapies (NASDAQ ITCI) opened at 11.11 on Friday. Intra-Cellular Therapies has a 52-week low of $7.85 and a 52-week high of $45.20. The stock has a 50 day moving average of $11.81 and a 200 day moving average of $12.48. The stock’s market capitalization is $482.44 million.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.33. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.03 million. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The firm’s revenue for the quarter was down 52.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.71) EPS. On average, equities research analysts forecast that Intra-Cellular Therapies will post ($2.43) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc. (ITCI) Upgraded at ValuEngine” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/21/intra-cellular-therapies-inc-itci-upgraded-at-valuengine.html.

A number of large investors have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Intra-Cellular Therapies by 0.3% in the first quarter. FMR LLC now owns 6,511,541 shares of the biopharmaceutical company’s stock valued at $105,813,000 after buying an additional 21,305 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Intra-Cellular Therapies by 7.3% in the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after buying an additional 186,165 shares in the last quarter. BB Biotech AG increased its stake in shares of Intra-Cellular Therapies by 11.7% in the second quarter. BB Biotech AG now owns 2,150,000 shares of the biopharmaceutical company’s stock valued at $26,703,000 after buying an additional 225,000 shares in the last quarter. Wasatch Advisors Inc. increased its stake in shares of Intra-Cellular Therapies by 65.1% in the second quarter. Wasatch Advisors Inc. now owns 1,659,513 shares of the biopharmaceutical company’s stock valued at $20,611,000 after buying an additional 654,400 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Intra-Cellular Therapies by 10.4% in the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after buying an additional 94,763 shares in the last quarter. 66.66% of the stock is owned by institutional investors and hedge funds.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.